

FOLEY & LARDNER
ATTORNEYS AT LAW
WASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 500
WASHINGTON, D.C. 20007-5109
TELEPHONE: (202) 672-5300
FACSIMILE: (202) 672-5399

FACSIMILE TRANSMISSION

Total # of Pages 5 (including this page)

TO:	PHONE:	FAX #:
Examiner Kamal Saeed U.S. PATENT AND TRADEMARK OFFICE	(703) 308-4592	(703) 746-5208


From: Stephen B. Maebius
Sender's Direct Dial: (202) 672-5569
Date: September 29, 2003
Client/Matter No: 065691/0199
Serial No.: 09/622,645
User ID No: 3663

MESSAGE:

I hereby certify that a copy of the Information Disclosure Statement and Form PTO-1449 is being transmitted to the U.S. Patent and Trademark Office by facsimile, addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

on September 29, 2003.


Vickie L. Willis

If there are any problems with this transmission or if you have not received all of the pages, please call (202) 672-5422.

Operator:	Time Sent:	Return Original To:
		Vickie Willis

CONFIDENTIALITY NOTICE: THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENTS NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION, AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR ANY AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 065691/0199

Applicant: Erwann LORET et al.
Title: ANTI-RETROVIRAL FUNCTIONALIZED AROMATIC COMPOUNDS
Serial No.: 09/633,645
Filed: September 8, 2000
Examiner: Unassigned
Art Unit: 1626

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicant's duty of disclosure pursuant to 37 CFR 1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR 1.97 and 1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie prior art reference against the claims of the present application.

Serial No. 09/622,645

Attorney Docket No. 065691/0199

TIMING OF THE DISCLOSURE

The instant Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action on the merits (first scenario). If that is not the case, such as in a second scenario in which a first Office Action on the merits has been mailed before the filing of the instant Information Disclosure Statement, a certification or fee is required. In that case, applicants provide a certification below in lieu of a fee. If that is not the case, such as in a third scenario in which a Notice of Allowance has been mailed before the filing of the instant Information Disclosure Statement, a certification and fee are required. In that case, see the certification provided below, and also the PTO is authorized to obtain the necessary fee to have this Information Disclosure Statement considered, from Foley & Lardner Deposit Account 19-0741.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

Respectfully submitted,

August 28, 2001
Date

for Philip J. Artale Reg. No.
Stephen B. Mabius 38,819
Registration No. 35,264

FOLEY & LARDNER
Suite 500
3000 K Street, N.W.
Washington, D.C. 20007-5109
(202) 672-5300

Page 1 of 2

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 065691-0199	SERIAL NO. 09/622,645
INFORMATION DISCLOSURE CITATION Date: August 28, 2001 (Use several sheets if necessary)		APPLICANT Erwann LORET et al.	
		FILING DATE 09/08/2000	GROUP ART UNIT 1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KS	A1	ARTICLE, Erwann P. Loret, et al. - "Activating Region of HIV-1 Tat Protein: Vacuum UV Circular Dichroism and Energy Minimization", 1991, Volume 34, pages 6013-6023.						
KS	A2	ARTICLE, Catherine J. Gregoire, et al. - "Conformational Heterogeneity in Two Regions of TAT Results in Structural Variations of This Protein as a Function of HIV-1 Isolates", September, 1996, Volume 271, pages 22641-22646.						
KS	A3	ARTICLE, P. Bayer, et al. - "Structural Studies of HIV-1 Tat Protein", 1995 Academic Press Limited, pages 529-535						
KS	A4	ARTICLE, Erwann P. Loret, et al. - "Circular Dichroism and Molecular Modeling Yield a Structure for the Complex of Human Immunodeficiency Virus Type 1 Trans-Activation Response RNA and the Binding Region of Tat, the Trans-acting Transcriptional Activator", October 1992, Volume 89, pages 9734-9738						
KS	A5	ARTICLE, Aviva Lapidot, et al. - "Tetrahydropyrimidine Derivatives Inhibit Binding of a Tat-like, Arginine-Containing Peptide, To HIV TAR RNA in Vitro", 1995, pages 33-38.						
KS	A6	ARTICLE, M. Witvrouw, et al. - "Broad-spectrum Antiviral Activity and Mechanism of Antiviral Action of the Fluorouinolone Derivative K-12", 1998 International Medical Press, pages 403-411.						
KS	A7	ARTICLE, Masanori Baba, et al. - "Inhibition of Human Immunodeficiency Virus Type 1 Replication and Cytokine Production by Fluroquinolin Derivatives", 1998, pages 1097-1103.						

Page 2 of 2

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 065691-0199		SERIAL NO. 09/622,645	
INFORMATION DISCLOSURE CITATION Date: August 28, 2001 (Use several sheets if necessary)				APPLICANT Erwann LORET et al.			
				FILING DATE 09/08/2000		GROUP ART UNIT 1626	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
KS	A8	ARTICLE, Ming-Chung Jiang, et al. - "Inhibition of HIV-1 Tat-Mediated Transactivation", 1996, Volume 226, pages 1-7.					
KS	A9	ARTICLE, Ming-Chu Hsu, et al. - "Inhibition of Type 1 human Immunodeficiency Virus Replication by a Tat Antagonist to Which the Virus Remains Sensitive After Prolonged Exposure in Vitro", July 1993, Volume 90, pages 6395-6399.					
KS	A10	ARTICLE, Ming-Chu Hsu, et al. - "Inhibition of HIV Replication in Acute and Chronic Infections in Vitro by a Tat Antagonist", December, 1991, Volume 254, pages 1799-1802.					
KS	A11	ARTICLE, Hsiao-Kuey Chang, et al. - "Block of HIV-1 Infection by a Combination of Antisense Tat RNA and TAR Decoys: a Strategy for Control of HIV-1", 1994, pages 208-216					
KS	A12	ARTICLE, Lori Pearson, et al. - "A Transdominant Tat Mutant That Inhibits Tat-induced Gene Expression From the Human Immunodeficiency Virus Long Terminal Repeat", July 1990, Volume 87, pages 5079-5083.					
KS	A13	ARTICLE, David Harich, et al. - "Tat is Required For Efficient HIV-1 Reverse Transcription", 1997, Volume 16, pages 1224-1235.					
KS	A14	ARTICLE, Athina Efthymiadis, et al. - "The HIV-1 Tat Nuclear Localization Sequence Confers Novel Nuclear Import Properties", 1998, Volume 273, pages 1623-1628.					
KS	A15	ARTICLE, Eric Vives, et al. - "A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates Through the Plasma Membrane and Accumulates in the Cell Nucleus", 1997, Volume 272, pages 16010-16017.					
	A16	ARTICLE, T. Kevin Howcroft, et al. - "Repression of MHC Class I Gene Promoter Activity by Two-Exon Tat of HIV", May 1993, Volume 260, pages 1320-1322.					
	A17	ARTICLE, Michael O. Westendorp, et al. - "HIV-1 Tat Potentiates TNF-induced NF- κ B Activation and Cytotoxicity by Altering the Cellular Redox State", 1995, Volume 14, pages 546-554.					
	A18	ARTICLE, Barbara Ensoll, et al. - "Synergy Between Basic Fibroblast Growth Factor and HIV-1 Tat Protein in Induction of Kaposi's Sarcoma", October 1994, Volume 371, pages 674-680.					
	A19	ARTICLE, Michael O. Westendorp, et al. - "Sensitization of T Cells to CD95-Mediated Apoptosis by HIV-1 Tat and gp120", June 1995, Volume 375, pages 497-500.					
	A20	ARTICLE, Erwann P. Loret, et al. - "Circular Dichroism and Molecular Modeling Yield a Structure for the Complex of Human Immunodeficiency Virus Type 1 Trans-activation Response RNA and the Binding Region of Tat, the Trans-acting Transcriptional Activator", October 1992, Volume 89, pages 9734-9738.					
	A21	ARTICLE, Ben Berkhout, et al. - "TAR-Independent Activation of the HIV-1 LTR: Evidence That Tat Requires Specific Regions of the Promoter", August 1990, Volume 62, pages 757-767.					
KS	A22	ARTICLE, Suresh K. Arya, et al. - "Trans-Activator Gene of Human T-Lymphotropic Virus Type III (HTLV-III)", July 1985, Volume 229, pages 69-73.					

Kamal Saeed

002.616023

Received from < > at 9/29/03 12:15:47 PM [Eastern Daylight Time]